Evidence map›Paper›PMID 41911254›Full record

ArticlePloS one2026

Resistance gene profiling of beta-lactamase and carbapenemase in gram-negative blood isolates: A tertiary care hospital.

Daniel Beshah, Tesfaye Sisay Tessema, Gurja Belay Woldemichael, Esmael Besufikad Belachew, Dawit Hailu Alemayehu, Abebech Tesfaye, Dessalegn Abeje Tefera, Solomon Gizaw Derese, Tizazu Zenebe Zelelie, Abera Admasie and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Daniel BeshahDepartment of Medical Laboratory Science, School of Biomedical and Laboratory Science, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.ORCID https://orcid.org/0000-0003-1510-8711
Tesfaye Sisay TessemaInstitute of Biotechnology, Addis Ababa University, Addis Ababa, Ethiopia.
Gurja Belay WoldemichaelDepartment of Microbial, Cellular, and Molecular Biology, College of Natural and Computational Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Esmael Besufikad BelachewArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Dawit Hailu AlemayehuArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Abebech TesfayeArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Dessalegn Abeje TeferaArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Solomon Gizaw DereseDepartment of Microbiology, Immunology, and Parasitology, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Tizazu Zenebe ZelelieDepartment of Medical Laboratory Science, Debre Berhan University, Debre Berhan, Ethiopia.
Abera AdmasieDepartment of Biology (Biotechnology program), College of Natural and Computational Sciences, Arba Minch University, Arba Minch, Ethiopia.
Tamrat AbebeDepartment of Microbiology, Immunology, and Parasitology, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Adey Feleke DestaDepartment of Microbial, Cellular, and Molecular Biology, College of Natural and Computational Sciences, Addis Ababa University, Addis Ababa, Ethiopia.ORCID https://orcid.org/0000-0001-6431-7363

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global rise in antimicrobial resistance is largely driven by DNA-encoded, antibiotic-hydrolyzing enzymes. This study aimed to determine the prevalence of ESBL, AmpC-BL, MBL, and carbapenemase genes. A cross-sectional study was conducted from September 2018 to March 2019 using standard microbiological and molecular methods. Among 231 Gram-negative bacterial isolates, 176 (76.2%) carried beta-lactamase genes confirmed by PCR. ESBLs were detected in 117 (50.6%), MBLs in 50 (21.6%), carbapenemases in 46 (19.9%), and AmpC-BLs in 22 (9.5%). The most frequent carriers were Klebsiella pneumoniae, Escherichia coli, and Acinetobacter species. The dominant ESBL genes were blaCTX-M (85.2%) and blaTEM (79.5%), with blaBEL (17.2%) surpassing blaSHV (9.8%), indicating a shift in resistance patterns, while among AmpC genes, blaFOX (39.4%) and blaCITM (36.4%) were the most prevalent. The blaOXA-23 (40.6%) and blaKPC (14.5%) were the most common carbapenemase genes, while blaNDM (39.1%) and blaVIM (34.8%) dominated among MBLs. The high prevalence of blaOXA-23 in Ethiopia is a significant finding, which I have not found evidence of in similar African or Asian settings. A comparable trend in Taiwan suggests medical tourism may contribute to the spread of resistant bacteria. These findings highlight the critical importance of continuous molecular surveillance and indicate that factors like medical tourism may contribute to the international dissemination of resistant strains.

Indexed as

Bacterial Proteinsbeta-LactamasesGram-Negative BacteriaAnti-Bacterial AgentsCross-Sectional StudiesHumansMicrobial Sensitivity TestsTertiary Care CentersAnti-Bacterial AgentsBacterial Proteinsbeta-Lactamasescarbapenemase

Identifiers

PMID41911254
PMCPMC13035159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.